Reduction in Share Capital, Reverse-Stock Split Approved by Epigenomics Shareholders

The company said that the difference in share capital resulting from the reduction would be credited to the capital reserve, and "would serve in the full amount to offset depreciation and cover other losses."

Full-text access for registered users only. Existing users login here.
New to GenomeWeb? Register here quickly for free access.